PTEN hamartoma tumor syndrome: An overview

被引:225
作者
Hobert, Judith A. [1 ]
Eng, Charis [1 ,2 ,3 ,4 ]
机构
[1] Cleveland Clin, Genom Med Inst, Lerner Res Inst, Cleveland, OH 44195 USA
[2] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA
[3] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA
[4] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH USA
关键词
PHTS; Cowden syndrome; PTEN; Bannayan-Riley-Ruvalcaba syndrome; RILEY-RUVALCABA-SYNDROME; COWDEN-SYNDROME; GERMLINE MUTATIONS; BREAST-CANCER; PHOSPHOINOSITOL-3-KINASE/AKT PATHWAY; JUVENILE POLYPOSIS; SUPPRESSOR GENE; DISEASE; SPECTRUM; DYSREGULATION;
D O I
10.1097/GIM.0b013e3181ac9aea
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
PTEN hamartoma tumor syndrome (PHTS) encompasses four major clinically distinct syndromes associated with germline mutations in the tumor suppressor PTEN. These allelic disorders, Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, and Proteus-like syndrome are associated with unregulated cellular proliferation leading to the formation of hamartomas. Thus far, an increased risk of malignancy has only been documented in Cowden syndrome; however, current recommendations advise that all individuals with PTEN hamartoma turner syndrome follow the cancer surveillance strategies suggested for Cowden syndrome until further data indicate otherwise. Because any individual phenotypic feature of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome are frequently present in the general population, many individuals often go undiagnosed and consequently do not benefit from available cancer surveillance strategies. Therefore, it is critical for clinicians to recognize the phenotypic features associated with these syndromes to accurately diagnose and provide preventative care. This overview details the clinical description of the PTEN hamartoma tumor syndrome and associated disorders, their diagnosis and molecular/genetic testing, as well as differential diagnosis for assessment of other hamartoma-associated syndromes. Genet Med 2009:11(10):687-694.
引用
收藏
页码:687 / 694
页数:8
相关论文
共 38 条
[1]  
Biesecker LG, 1999, AM J MED GENET, V84, P389, DOI 10.1002/(SICI)1096-8628(19990611)84:5<389::AID-AJMG1>3.0.CO
[2]  
2-O
[3]  
Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO
[4]  
2-0
[5]  
BROWNSTEIN MH, 1978, CANCER-AM CANCER SOC, V41, P2393, DOI 10.1002/1097-0142(197806)41:6<2393::AID-CNCR2820410644>3.0.CO
[6]  
2-K
[7]   Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations [J].
Butler, MG ;
Dasouki, MJ ;
Zhou, XP ;
Talebizadeh, Z ;
Brown, M ;
Takahashi, TN ;
Miles, JH ;
Wang, CH ;
Stratton, R ;
Pilarski, R ;
Eng, C .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (04) :318-321
[8]   Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis [J].
Chung, JH ;
Eng, C .
CANCER RESEARCH, 2005, 65 (18) :8096-8100
[9]  
Cohen M M Jr, 1979, Birth Defects Orig Artic Ser, V15, P291
[10]  
Cohen M M Jr, 1999, Adv Pediatr, V46, P441